{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:18:03Z","timestamp":1791249483244,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,4]],"date-time":"2011-09-04T00:00:00Z","timestamp":1315094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s10549-011-1749-y","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T16:53:44Z","timestamp":1315328024000},"page":"111-116","source":"Crossref","is-referenced-by-count":16,"title":["Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer"],"prefix":"10.1007","volume":"131","author":[{"given":"Devika","family":"Gajria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Feigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Theodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Drullinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford A.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A.","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,4]]},"reference":[{"key":"1749_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"D Slamon","year":"1987","unstructured":"Slamon D et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"issue":"3","key":"1749_CR2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719\u2013726","journal-title":"J Clin Oncol"},{"issue":"10","key":"1749_CR3","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9,840. J Clin Oncol 26(10):1642\u20131649","journal-title":"J Clin Oncol"},{"key":"1749_CR4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"M Cobleigh","year":"1999","unstructured":"Cobleigh M et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639\u20132648","journal-title":"J Clin Oncol"},{"issue":"11","key":"1749_CR5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"10","key":"1749_CR6","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","volume":"19","author":"AD Seidman","year":"2001","unstructured":"Seidman AD et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19(10):2587\u20132595","journal-title":"J Clin Oncol"},{"issue":"18","key":"1749_CR7","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","volume":"26","author":"HL Gomez","year":"2008","unstructured":"Gomez HL et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18):2999\u20133005","journal-title":"J Clin Oncol"},{"issue":"6","key":"1749_CR8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","volume":"19","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ et al (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19(6):1068\u20131074","journal-title":"Ann Oncol"},{"issue":"6","key":"1749_CR9","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","volume":"20","author":"KL Blackwell","year":"2009","unstructured":"Blackwell KL et al (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20(6):1026\u20131031","journal-title":"Ann Oncol"},{"issue":"26","key":"1749_CR10","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733\u20132743","journal-title":"N Engl J Med"},{"issue":"9","key":"1749_CR11","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","volume":"12","author":"JA Oshaughnessy","year":"2001","unstructured":"Oshaughnessy JA et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer. Ann Oncol 12(9):1247\u20131254","journal-title":"Ann Oncol"},{"issue":"4","key":"1749_CR12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792\u2013799","journal-title":"J Clin Oncol"},{"issue":"9","key":"1749_CR13","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","volume":"16","author":"M Mackean","year":"1998","unstructured":"Mackean M et al (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer. J Clin Oncol 16(9):2977\u20132985","journal-title":"J Clin Oncol"},{"issue":"9","key":"1749_CR14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdl134","volume":"17","author":"R Leonard","year":"2006","unstructured":"Leonard R et al (2006) Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 17(9):1379\u20131385","journal-title":"Ann Oncol"},{"issue":"18_suppl","key":"1749_CR15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/jco.2007.25.18_suppl.1031","volume":"25","author":"M Stockler","year":"2007","unstructured":"Stockler M et al (2007) A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 25(18_suppl):1031 (Meeting Abstracts)","journal-title":"J Clin Oncol"},{"issue":"18_suppl","key":"1749_CR16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/jco.2006.24.18_suppl.570","volume":"24","author":"C Soto","year":"2006","unstructured":"Soto C et al (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential versus combined therapy results from a MOSG randomized phase III trial. J Clin Oncol (Meeting Abstracts) 24(18_suppl):570","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"27","key":"1749_CR17","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2005.05.1383","volume":"24","author":"JL Blum","year":"2006","unstructured":"Blum JL et al (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24(27):4384\u20134390","journal-title":"J Clin Oncol"},{"key":"1749_CR18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/264542a0","volume":"264","author":"L Norton","year":"1976","unstructured":"Norton L et al (1976) Predicting the course of gompertzian growth. Nature 264:542\u2013545","journal-title":"Nature"},{"key":"1749_CR19","doi-asserted-by":"crossref","unstructured":"Traina T et al (2010) Optimizing chemotherapy dose and schedule by norton-simon mathematical modeling. Breast Dis 31(1):7\u201318","DOI":"10.3233\/BD-2009-0290"},{"key":"1749_CR20","unstructured":"Traina T et al (2006) In vivo activity of a novel regimen of capecitabine in a breast cancer xenograft model breast cancer research and treatment. Breast Cancer Res Treat 100(Suppl. 1):279\u2013280"},{"issue":"11","key":"1749_CR21","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2007.13.8388","volume":"26","author":"TA Traina","year":"2008","unstructured":"Traina TA et al (2008) Phase I study of a novel capecitabine schedule based on the norton-simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26(11):1797\u20131802","journal-title":"J Clin Oncol"},{"issue":"10","key":"1749_CR22","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2\u2013negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252\u20131260","journal-title":"J Clin Oncol"},{"key":"1749_CR23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1158\/0008-5472.SABCS-09-42","volume":"69","author":"A Brufsky","year":"2009","unstructured":"Brufsky A et al (2009) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69:42 (MeetingAbstracts)","journal-title":"Cancer Res"},{"key":"1749_CR24","doi-asserted-by":"crossref","unstructured":"Gajria D et al (2011) Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer (epublication)","DOI":"10.1002\/cncr.25992"},{"issue":"2","key":"1749_CR25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485\u2013493","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1749-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1749-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T06:36:44Z","timestamp":1592894204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1749-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1749"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1749-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,4]]}}}